Bayer's first innovation center in China, the Bayer E-Town Open Innovation Center, began operations in Beijing E-town's BioPark on Nov 15. On the same day, Bayer's global life sciences co-creation platform, Bayer Co.Lab, was also established at the BioPark.

These two developments further strengthen the full-chain innovation ecosystem of the biotechnology and health industries in Beijing E-Town, injecting strong momentum into the region's high-quality development.

Bayer is the only biopharmaceutical company in Beijing that has consistently achieved an output value exceeding 10 billion yuan ($1.41 billion) for 13 consecutive years. It is also one of the few foreign enterprises in Beijing that has both a global research and development center and a world-class product supply center. The company established itself in Beijing E-Town in 1995, marking 30 years of presence there. Bayer's prescription drug factory located in Beijing E-Town, has now become Bayer's largest prescription drug packaging base globally.

As a key component of Bayer's "Rooted in China, Linked Globally" strategy, the Bayer E-town Open Innovation Center deeply integrates resources from industry, education, research, and entrepreneurship. It is dedicated to incubating local innovative pharmaceutical companies and supporting the international expansion of local innovative drugs, thereby strengthening the entire chain of innovation in China. Additionally, the center collaborates with high-level research and clinical institutions to enhance basic research and clinical translation capabilities, thereby facilitating data-driven digital business innovation.

On the same day, Bayer Co.Lab, Bayer's global life science co-creation platform, was simultaneously established in the BioPark. In the future, it will synergize with the Bayer E-town Open Innovation Center to connect global resources and collaboration networks, deepen local innovation partnerships, promote the transformation of early-stage innovative achievements, and support the development and internationalization of local biopharmaceutical startups. This initiative aims to integrate deeply into the global pharmaceutical industry and innovation ecosystem.

Notably, the BioPark, which has continuously attracted Bayer's strategic investments, has four major functional zones: a headquarters cluster area, a medical-engineering integration area, a research and development transformation area, and a pharmaceutical intelligent manufacturing area.

The park's key project, a life and health industry-education integration base, has already established partnerships with renowned domestic universities such as Tsinghua University, Peking University, and Beihang University to jointly promote organized industrial innovation and talent cultivation. Additionally, the park plans to establish an international clinical medical research center, aiming to develop a world-class clinical research hospital focused on medical research and driven by innovation and transformation.

The official launch of the Bayer E-town Open Innovation Center at the BioPark marks a new starting point for Bayer and the Beijing E-Town as they embark on the next 30 years of collaboration.